CORE D: HUMAN MAB CORE

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 我们的Cobre启动的人源单抗核心装置 OMRF是世界上为数不多的生产 全人类、全长、抗原特异性抗体和唯一 为科布雷调查人员提供这项服务的人。我们的 制造流感特异性抗体的方法最近已经开始 发表(Wrammert等人，《自然》。2008年5月29日； 453(7195)：667-71，以及Smith等人，《自然协议》2009； 4(3)：372-84)，代表着 抗体技术。在Cobre的支持下，我们最近 扩大了我们感兴趣的抗原，并产生了高水平的 炭疽致死毒素的亲和力、保护性抗体和各种 肺炎链球菌外壳多糖。我们的主要目标是 与其他Cobre调查人员合作定义人类 疫苗接种后的免疫反应和产生人 以此来补充他们的研究。我们会 从OMRF开始，在时间和资源允许的情况下，我们将扩大 这些为俄克拉荷马大学健康中心的调查人员提供的服务 俄克拉何马州立大学科学中心(OUHSC)等 俄克拉荷马州以外的科布雷机构。一次这样的合作 OUHSC的巴拉德实验室将允许我们评估 急性或再激活后抗体分泌细胞的产生 感染，而不是接种疫苗。产生的能力 自然感染后的抗体会大大增加数量 我们可以研究病原体的反应。这些抗体也会 给我们一个真实的关于抗体对 人类疾病中的各种保护性表位。在所有这些案例中， 产生的抗体将被检测为被动抗体。 免疫疗法。最后，我们将研究微阵列和 Biacore技术用于快速初步表征 产生抗体。筛查抗体的能力 同时对于大量的抗原也将允许我们 研究个人产生的抗体的特异性 自身免疫性疾病。总体而言，该核心将提供服务 这将使Cobre的研究人员能够生产出新的治疗方法 并探索各种人类免疫的新科学方向 健康和疾病方面的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Our COBRE-initiated Human Monoclonal Antibody Core Facility at OMRF is one of the few laboratories in the world that produces fully-human, full-length, antigen-specific antibodies and the only one that provides this service to COBRE investigators. Our process for making influenza-specific antibodies has been recently published (Wrammert et al., Nature. 2008 May 29; 453(7195):667-71, and Smith et al., Nature Protocols 2009; 4(3):372-84) and represents a significant breakthrough in antibody technology. With COBRE support, we have recently expanded our antigens of interest and have produced high affinity, protective antibodies to anthrax lethal toxin and various S. pneumoniae coat polysaccharides. Our primary goal is to collaborate with other COBRE investigators to define human immune responses after vaccination and to generate human monoclonal antibodies to supplement their research. We will begin at OMRF and as time and resources allow, we will expand these services to investigators at the Oklahoma University Health Sciences Center (OUHSC), Oklahoma State University and other COBRE institutions outside Oklahoma. One such collaboration with the Ballard lab at OUHSC will allow us to evaluate the generation of antibody secreting cells after acute or reactivated infection, rather than vaccination. The ability to generate antibodies after natural infection will greatly increase the number of pathogen responses we can study. These antibodies will also give us a true snapshot of the contribution of antibodies to various protective epitopes in human disease. In all these cases, the antibodies produced will be explored as passive immunotherapeutics. Finally, we will investigate microarray and Biacore technologies for the rapid initial characterization of the antibodies produced. The ability to screen antibodies simultaneously for large numbers of antigens will also allow us to study the specificities of antibodies produced by individuals with autoimmune disorders. Overall, this Core will provide services which will allow COBRE investigators to produce new therapeutics and explore new scientific directions in a variety of human immune responses in health and disease.